SynthesisFrontiers in immunology2026
Influencing factors for rapidly progressive interstitial lung disease in patients with anti-MDA5 antibody-positive dermatomyositis: a systematic review and meta-analysis.
Synthesis in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The development of rapidly progressive interstitial lung disease (RP-ILD) in patients with anti-MDA5-positive dermatomyositis-associated interstitial lung disease (MDA5+ DM-ILD) is a major cause of adverse outcomes, including mortality. This study aimed to identify factors influencing the occurrence of RP-ILD in patients with MDA5+ DM-ILD. Methods: A systematic search was conducted in PubMed, EMBASE, the Cochrane Library, Web of Science, and Scopus for studies investigating factors associated with RP-ILD in MDA5+ DM-ILD, with the search period extending to January 1, 2026. The quality of the included studies was assessed using the Newcastle-Ottawa Scale (NOS). Meta-analysis was performed using Stata 18.0 software. Results: Fifteen studies were included in the meta-analysis, all of which were of high quality, with an average NOS score of 7.9. The meta-analysis revealed that male sex (OR = 1.99, 95% CI: 1.27-3.12), advanced age (OR = 2.54, 95% CI: 1.40-4.60), disease duration <3 months (OR = 3.23, 95% CI: 2.23-4.70), fever (OR = 2.46, 95% CI: 1.55-3.90), anti-Ro52 antibody positivity (OR = 5.05, 95% CI: 3.21-7.96), elevated C-reactive protein (CRP) (OR = 2.29, 95% CI: 1.78-2.94), elevated neutrophil-to-lymphocyte ratio (NLR) (OR = 2.29, 95% CI: 1.28-4.08), elevated lactate dehydrogenase (LDH) (OR = 3.39, 95% CI: 2.20-5.22), elevated aspartate aminotransferase (AST) (OR = 1.03, 95% CI: 1.00-1.06), elevated alanine aminotransferase (ALT) (OR = 2.42, 95% CI: 1.22-4.80), elevated serum ferritin (SF) (OR = 3.81, 95% CI: 1.95-7.42), lymphopenia (OR = 2.14, 95% CI: 1.10-4.16), and elevated carcinoembryonic antigen (CEA) (OR = 3.38, 95% CI: 1.32-8.66) were risk factors for RP-ILD. Conversely, arthralgia/arthritis (OR = 0.26, 95% CI: 0.16-0.44) and lymphocytosis (OR = 0.17, 95% CI: 0.09-0.31) were identified as potential protective factors. Conclusion: This study explored potential risk and protective factors associated with the development of RP-ILD in patients with MDA5+ DM-ILD, providing a basis for early identification and management. Systematic review registration: https://www.crd.york.ac.uk/prospero/, identifier CRD420261287925.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.